Financial Times FT.com

Resources

Principal content

Addition of concept of “collective dominance” to Indian Competition Act will strengthen country’s antitrust regulator

A proposed amendment to India’s Competition Act 2002 could see the country “leapfrog” from a relatively backward approach to the issue of collective dominance to a stance akin to that of the European Union. by PaRR

Barnes & Noble’s Nook looks to textbooks, sources say

Tablet maker set to launch digital textbook platform. by dealReporter

Managed Healthcare first round bids due in early February, sources say

High price sought amid keen private equity interest. by mergermarket

Global Display’s atypical CEO breeds loyalty

CEO’s deep technical knowledge and easygoing style retains staff. by dealReporter

Eurasian Economic Commission to develop competition law by July 2013 - minister

In an exclusive interview with PaRR, the Minister for Trade of the Eurasian Economic Commission outlines the body’s plans for a model law on competition later this year for the single economic area of Russia, Kazakhstan and Belarus. by PaRR

NSFR implementation uncertain after Basel III compromise on LCR phase-in

Politics and banks put regulators on defensive meaning minimum stable funding rules could be delayed or even dropped. by dealReporter

Baxter’s Gammagard unlikely to be successful in mild-to-moderate Alzheimer’s

Previous failures with drugs that have the same target do not bode well for success. by BioPharm Insight

CADE probes into LCD and CRT segments expose challenges facing Brazilian enforcement

Nascent CADE encounters growing pains in first cartel investigations. by PaRR

Ridley Terminals mandates Macquarie for privatisation

Market sounding under way. by mergermarket

Dubai Group strikes deal with dissenting banks

New exit offer heads off arbitration. by dealReporter

Noodles & Company interviewing advisers for initial public offering

Turkey’s merger control system to benefit from higher thresholds and streamlined test - lawyers

Merck’s Zetia/atorvastatin combo pill unlikely to gain FDA nod until cardiovascular impact results available

High hopes for buyouts in 2013 – analysis

DoJ has hands off Google (mostly); could risk ‘holy war’ if it attempts do-over

How Best Buy’s Schulze missed Christmas

High multiples and attractive dynamics attract PE firms to flow control sector

German competition law reform delayed until next year

Merck, BMS/AZ, Novartis face 2013 German price cuts on DPP-4 diabetes drugs

Hillshire’s doubtful growth may attract disrupter

Shire’s strong Vyvanse data and lack of abuse potential bode well for use in EU paediatrics – psychiatrists

Chinese leadership change, not island spat, at heart of MOFCOM’s Japanese bottleneck

Sprouts Farmers Markets to go public in 1H13

Permira-backed Netafim seeks China partner to grab share of irrigation market

Vertex’ Kalydeco faces UK price pushback though solid cystic fibrosis data warrants funding settlement

Sanofi/Zealand’s antidiabetic lixisenatide triggers mixed feelings on prospects for showing cardiovascular benefit

Theravance’s antibiotic Vibativ gasps for breath in hospital pneumonia

The Investment Dar debt deliberations include claim reclassification

LodgeNet plans to clear debt hurdles with lift from Colony Capital

Economist Shelanski leads candidates for FTC chairmanship

Postsecondary education M&A creeping back - Analysis

China’s inland LNG capacity expansion presents major export opportunities for foreign technology providers

Panasonic seeks to exit Sanyo-brand TV business, sources say

China to release its first biosimilars guidelines, aims to speed up drug registration process

Timing of FTC ‘Big Google’ case points toward settlement

Grandall partner to lead new antitrust-focused law firm in China

Arena’s Belviq to be unfazed by DEA scheduling as weight-loss drug not seen as addictive

Depomed’s clinical trial data for hot flashes drug Serada warrants US approval though FDA analysis gives pause

FTC chairman fights back against Phoebe Putney brief

TW Telecom seen considering sale

Smart & Final sale advances to final round

MBIA’s Bear Stearns RMBS fraud case could spark others

MetroPCS engages suitors, source says

Zabeel Investments’ debt restructuring disrupted

GSK’s Votrient expected to show noninferiority to Pfizer’s Sutent, no effect on front-line RCC uptake

Merz’s Xeomin and Belotero will impact aesthetics market post Allergan’s injunction

Proposed EMA guidelines to further steer anti-infectives developers to seek European drug approvals before US - experts

Repros in patent predicament for oral testosterone contender Androxal – lawyers

Fal Oil debt restructuring jeopardized by missing oil

Chinese companies face tough sell on US IPOs